XOMA News and Press, XOMA Corporation From 05/03/21

EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc. (Janssen), as a result of the first patient dosed in a Phase 3 clinica...

As April 2021 comes to a close, we look back at the new preferred stocks and ETDs introduced during the month, offering annual yields ranging from 4.625 to 8.375 percent. Here is a comparison, against highest quality preferred stocks in our coverage universe, as ranked by our internal...

The COVID-19 pandemic brought a renewed interest to biotech firms, with many searching for treatments and vaccines. This led to strong returns for many top biotech stocks. But there are smaller, lesser know companies that are also poised for strong returns such as Vanda Pharmaceuticals (VNDA)...

EMERYVILLE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. (Nasdaq: AFMD) innate cell engager (ICE ® ) programs for which...

Raised aggregate gross proceeds of $40 million Depositary shares represent an interest in 8.375% Series B Cumulative Perpetual Preferred Stock EMERYVILLE, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Compan...

Xoma (XOMA) has priced its public offering of 1.4M depositary shares at an IPO price of $25.00/share, for gross proceeds of $35M.Each depositary share represents a 1/1000th fractional interest in a share of the Company’s 8.375% Series B Cumulative Perpetual Preferred Stock. Underw...

EMERYVILLE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the pricing of its underwritten registered public offering of 1,400,000 depositary shares at an initial public offering price of $25.0...

An update on the 20 life sciences companies Numenor Capital has profiled so far range from cell therapy companies like SQZ Biotech and Orchard Therapeutics to biologics platforms like Pandion. The best performing investment, over 170% return, so far has been Pandion Therapeutics that ...

EMERYVILLE, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of depositary shares, each representing 1/1000 th fractional interest ...

Should Investors Be Watching These Top Health Care Stocks Right Now? Most would know that health care stocks are amongst the top performers throughout the current pandemic. Some might even say that the sector is among the best to invest in now. For one thing, the industry is hom...